Before joining Amyl, Damien worked as a Project Lead at Pharnext, focusing on neurodegenerative diseases, including Parkinson’s, Alzheimer’s, and ALS. He co-founded and served as CSO of Encefa for eight years, leading the development of a monoclonal anti-CD38 antibody for ALS. Damien holds an MSc in Biochemistry and Genetics from Agrocampus Rennes and a PhD in Neurosciences from Paris Sorbonne. He is currently the CSO of Amyl.